NCT03829891已完成不适用
A Randomized, Open-label, Controlled,Parallel-group Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus
Xijing Hospital2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2018年8月7日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Changes of blood sugar variation .
研究概览
简要总结
The investigators aimed to assess the efficacy and safety of Beinaglutide versus glargine , in individuals with type 2 diabetes who did not achieve adequate glycaemic control with oral antidiabetic drug.
详细描述
The investigators wonder in clinical hypoglycemic treatment for patients with hyperglycemia, whether to reduce fasting blood glucose or postprandial blood glucose first.
In this study, subjects with type 2 diabetes mellitus in combination with oral medication will be treated with basic insulin to reduce fasting blood glucose, or with beinaglutide to reduce postprandial blood glucose, in order to find out which one of controling blood glucose can be more effective and observe the change of blood fluctuation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent obtained before any trial-related activities
- •Male or female between the age of 18 and 70 years by the time of visit 1
- •Have been diagnosed as type 2 diabetes for at least half a year
- •Prestudy combination OAD therapy for at least 1 month(except glinides, DPP-VI inhibitor,insulin,GLP-1 receptor agonists ),
- •The dose of Sulfonylureas less than the half maximum dose of insert
- •7.5%≤HbA1c≤11.0% in recent 2 weeks or on visit 1(local lab test)
- •21Kg/m2≤BMI≤35Kg/m2
排除标准
- •Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods .
- •Current diagnosis or history of following:
- •Type 1 diabetes
- •Diabetes caused by impaired pancreas
- •Diabetes is the secondary diagnosis ,such as acromegaly,Cushing syndrome etc.
- •Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent acute complications of diabetes (eg. diabetes ketoacidosis, hyperosmolar coma) within 6months prior to screening.
- •Use of any glinides, DPP-VI inhibitor,GLP-1 receptor agonists within 3months prior to screening.Use of any insulin within 1months prior to screening.
- •History of allergy (such as systemic allergy, Vascular neuroedema, epidermal exfoliation, etc.)
- •Systemic use of glucocorticoids (oral or intravenous) continued for more than seven days in the past half year.
- •Triglyceride (fasting)> 4.5mmol/L at visit
- •Impaired liver function,such as manifested in one of the following situations:
- •Two consecutive measurements of AST or ALT in the first four weeks of the visit exceeded the maximum normal value by more than three times (local laboratory data)
- •Bilirubin synthesis and/or excretion disorders (such as hyperbilirubinemia) and other decompensated liver diseases such as coagulation,Blood disorders, hepatic encephalopathy, hypoproteinemia, ascites, esophageal variceal bleeding
- •Acute viral, active autoimmune, alcoholic and other types of hepatitis
- •Moderate to severe renal impairment or end-stage renal disease (estimated kidney) at visit or 4 weeks before visit (local data)Globular filtration rate < 60 mL/minNew York Heart Association (NYHA) Class III or IV congestive heart failure
- •Visit 1 has a major history of cardiovascular disease in the past three months, defined as myocardial infarction, coronary angioplasty or bypass surgery, valvular disease or repair, unstable angina, transient ischemic attack or cerebrovascular accident.
- •History of acute or chronic pancreatitis
- •History of gastrointestinal diseases, including gastrointestinal stoma anastomosis, intestinal resection, gastric cardiac syndrome, severe hernia, intestinal obstruction, intestinal ulcer
- •Malignant tumors (except cutaneous basal cell carcinoma, cervical carcinoma in situ and prostate cancer in situ) have been diagnosed in the past five years.
- •History of organ transplantation or AIDS
- •History of medullary thyroid cancer
- •History of alcohol or drug abuse in the past 12 months
- •Individuals or researchers who do not comply with the potential risks of the program are judged to be unsuitable for the study.
研究组 & 干预措施
Beinaglutide
Experimental
- Beinaglutide for 8 weeks,
- Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )
干预措施: glargine (Drug)
Beinaglutide
Experimental
- Beinaglutide for 8 weeks,
- Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )
干预措施: Beinaglutide (Drug)
glargine
Active Comparator
- Glargine for 8 weeks,
- Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )
干预措施: Beinaglutide (Drug)
glargine
Active Comparator
- Glargine for 8 weeks,
- Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )
干预措施: glargine (Drug)
结局指标
主要结局
Changes of blood sugar variation .
时间窗: Baseline and week 16
The proportion and rate of the fasting blood glucose control.
时间窗: Baseline and week 16
Proportion of patients with glycosylated hemoglobin < 7%.
时间窗: Baseline and week 16
次要结局
- Change of blood pressure(Baseline and week16)
- Change of body mass index report in kg/m^2(Baseline and week16)
- Waist-hip ration change(Baseline and week16)
- Change percentage of glycosylated hemoglobin(Baseline and week16)
- Inflammatory factors (MCP-1) change(Baseline and week16)
- Change of blood glucose(Baseline and week16)
- Change of blood lipids(Baseline and week16)
- Change of body weight report in kilograms(Baseline and week16)
- Oxidative Stress Indice (8-Iso-PGF2α) change(Baseline and week16)
- Inflammatory factors (hs-CRP) change(Baseline and week16)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin GlargineDiabetes Mellitus, Type 2NCT00976391GlaxoSmithKline586
已完成
3 期
Safety and Efficacy Study of Albiglutide in Type 2 DiabetesDiabetes Mellitus, Type 2NCT00849017GlaxoSmithKline309
已完成
3 期
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.Diabetes Mellitus, Type 2NCT01128894GlaxoSmithKline841
Unknown
4 期
Comparing Pregabalin and Placebo in Patients With Persistent Globus SensationGlobus SensationNCT05432843Universitaire Ziekenhuizen KU Leuven90
Unknown
3 期
Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II DiabetesDiabetes Mellitus, Type 2NCT03421119Cinnagen300